Search
Filter Results
Displaying 1–10 of 19 for “xlrs”
-
May 2, 2023
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Known as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
Dec 21, 2018
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.
-
Aug 28, 2023
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
The AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
X-linked retinoschisis (XLRS) is an inherited retinal disease causing vision loss due to splitting of the layers of the retina.
-
Jul 19, 2017
Twelve People Receive XLRS Gene Therapy in AGTC's Clinical Trial
AGTC’s gene therapy uses a human-engineered virus — and adeno-associated virus or AAV — to deliver normal copies of retinoschisin to the patient’s retina.
-
Jun 9, 2023
Recording Available: Foundation Insights Forum – May 31, 2023
The Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the inherited retinal disease community. The call took place on May 31, 2023.
-
X-linked retinoschisis (XLRS) is an inherited retinal diseasing causing vision loss due to splitting of the layers of the retina.
-
Oct 18, 2021
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
The emerging gene therapy is being designed to more safely reach the fovea
-
Dec 13, 2021
At only three months old, Brendon was diagnosed with x-linked juvenile retinoschisis (XLRS). But with several other family members also with XLRS, Brendon knew he could still follow his passions for science and space. Now 22, Brendon is an Aerospace Engineer, starting a PhD program at UCF, and was recently awarded the prestigious National Science Foundation’s Graduate Research Fellowship.
-
Jun 13, 2022
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
In its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.